Immunohistochemical Expressionof Sodium-dependent Glucose Transporter - 2 (SGLT-2) in Clear Cell Renal Carcinoma: Possible Prognostic Implications

Overview

Journal Int Braz J Urol

Specialty Urology

Date 2018 Dec 7

PMID 30521176

Citations 12

Authors

Minoru Kobayashi

Toshitaka Uematsu

Yuumi Tokura

Kohei Takei

Kazumasa Sakamoto

Takahiro Narimatsu

Akinori Nukui

Takao Kamai

Affiliations

Soon will be listed here.

Abstract

Purpose: Glucose is a major energy resource for tumor cell survival and growth, and its influx into cells is mainly carried out by facilitative glucose transporters (GLUTs). Sodium - dependent glucose transporters (SGLTs) have been highlighted as playing important roles in diabetic treatment. However, their potential roles in cancer remain unclear. We examined expression patterns of SGLTs in tumor tissues together with conventional pathological variables to determine prognostic significance in patients with renal cell carcinoma (RCC).

Materials And Methods: Nephrectomy specimens were obtained from 68 patients. GLUT - 1, - 2 and SGLT - 1, - 2 expression in tumor and adjacent normal tissues were analyzed by immunohistochemical staining, and intensity was quantified using an image analyzer.

Results: The four glucose transporters evaluated were broadly distributed in tumor tissues as well as throughout the normal parenchyma. There was no significant correlation between transporter expression and conventional pathological variables. However, increased SGLT - 2 expression was significantly associated with shorter overall survival (p < 0.01), regardless of metastatic status.

Conclusions: We propose possible prognostic significance of SGLT - 2 expression in human RCC. Given that glucose is a major energy resource for tumor cells and that glucose transport is largely mediated by SGLT, SGLT - 2 may serve as a possible therapeutic target in RCC.

Citing Articles

Advances in sodium-glucose transporter protein 2 inhibitors and tumors.

Wang J, Yang W Front Oncol. 2025; 15:1522059.

PMID: 40007997 PMC: 11850236. DOI: 10.3389/fonc.2025.1522059.

Exploring the Role of SGLT2 Inhibitors in Cancer: Mechanisms of Action and Therapeutic Opportunities.

Pandey A, Alcaraz Jr M, Saggese P, Soto A, Gomez E, Jaldu S Cancers (Basel). 2025; 17(3).

PMID: 39941833 PMC: 11815934. DOI: 10.3390/cancers17030466.

Research Progress of SGLT2 Inhibitors in Cancer Treatment.

Miao X, Zhang J, Huang W, Wang Y, Jin A, Cao J Drug Des Devel Ther. 2025; 19():505-514.

PMID: 39872633 PMC: 11771169. DOI: 10.2147/DDDT.S485755.

SGLT2 inhibitor promotes mitochondrial dysfunction and ER-phagy in colorectal cancer cells.

Anastasio C, Donisi I, Del Vecchio V, Colloca A, Mele L, Sardu C Cell Mol Biol Lett. 2024; 29(1):80.

PMID: 38811901 PMC: 11134909. DOI: 10.1186/s11658-024-00599-1.

Differential expression of and its downstream target in the main subtypes of renal cell carcinoma and their impact on patient survival.

Strikic A, Kokeza J, Ogorevc M, Kelam N, Vukoja M, dolonga P Front Oncol. 2023; 13:1287239.

PMID: 38053655 PMC: 10694430. DOI: 10.3389/fonc.2023.1287239.

References

Vestri S, Okamoto M, de Freitas H, Aparecida Dos Santos R, Nunes M, Morimatsu M . Changes in sodium or glucose filtration rate modulate expression of glucose transporters in renal proximal tubular cells of rat. J Membr Biol. 2001; 182(2):105-12. DOI: 10.1007/s00232-001-0036-y. View

Ishikawa N, Oguri T, Isobe T, Fujitaka K, Kohno N . SGLT gene expression in primary lung cancers and their metastatic lesions. Jpn J Cancer Res. 2001; 92(8):874-9. PMC: 5926833. DOI: 10.1111/j.1349-7006.2001.tb01175.x. View

Miyakita H, Tokunaga M, Onda H, Usui Y, Kinoshita H, Kawamura N . Significance of 18F-fluorodeoxyglucose positron emission tomography (FDG-PET) for detection of renal cell carcinoma and immunohistochemical glucose transporter 1 (GLUT-1) expression in the cancer. Int J Urol. 2002; 9(1):15-8. DOI: 10.1046/j.1442-2042.2002.00416.x. View

Warburg O . On the origin of cancer cells. Science. 1956; 123(3191):309-14. DOI: 10.1126/science.123.3191.309. View

Helmke B, Reisser C, Idzko M, Dyckhoff G, Herold-Mende C, Idzkoe M . Expression of SGLT-1 in preneoplastic and neoplastic lesions of the head and neck. Oral Oncol. 2003; 40(1):28-35. DOI: 10.1016/s1368-8375(03)00129-5. View

Linden K, Dehaan C, Zhang Y, Glowacka S, Cox A, Kelly D . Renal expression and localization of the facilitative glucose transporters GLUT1 and GLUT12 in animal models of hypertension and diabetic nephropathy. Am J Physiol Renal Physiol. 2005; 290(1):F205-13. DOI: 10.1152/ajprenal.00237.2004. View

Suganuma N, Segade F, Matsuzu K, Bowden D . Differential expression of facilitative glucose transporters in normal and tumour kidney tissues. BJU Int. 2007; 99(5):1143-9. DOI: 10.1111/j.1464-410X.2007.06765.x. View

Ozcan A, Shen S, Zhai Q, Truong L . Expression of GLUT1 in primary renal tumors: morphologic and biologic implications. Am J Clin Pathol. 2007; 128(2):245-54. DOI: 10.1309/HV6NJVRQKK4QHM9F. View

Lidgren A, Bergh A, Grankvist K, Rasmuson T, Ljungberg B . Glucose transporter-1 expression in renal cell carcinoma and its correlation with hypoxia inducible factor-1 alpha. BJU Int. 2007; 101(4):480-4. DOI: 10.1111/j.1464-410X.2007.07238.x. View

10.

Casneuf V, Fonteyne P, Van Damme N, Demetter P, Pauwels P, de Hemptinne B . Expression of SGLT1, Bcl-2 and p53 in primary pancreatic cancer related to survival. Cancer Invest. 2008; 26(8):852-9. DOI: 10.1080/07357900801956363. View

11.

Ganapathy V, Thangaraju M, Prasad P . Nutrient transporters in cancer: relevance to Warburg hypothesis and beyond. Pharmacol Ther. 2008; 121(1):29-40. DOI: 10.1016/j.pharmthera.2008.09.005. View

12.

Preitner F, Bonny O, Laverriere A, Rotman S, Firsov D, Da Costa A . Glut9 is a major regulator of urate homeostasis and its genetic inactivation induces hyperuricosuria and urate nephropathy. Proc Natl Acad Sci U S A. 2009; 106(36):15501-6. PMC: 2741280. DOI: 10.1073/pnas.0904411106. View

13.

Czernin J, Benz M, Allen-Auerbach M . PET/CT imaging: The incremental value of assessing the glucose metabolic phenotype and the structure of cancers in a single examination. Eur J Radiol. 2010; 73(3):470-80. DOI: 10.1016/j.ejrad.2009.12.023. View

14.

Blais A . Expression of Na(+)-coupled sugar transport in HT-29 cells: modulation by glucose. Am J Physiol. 1991; 260(6 Pt 1):C1245-52. DOI: 10.1152/ajpcell.1991.260.6.C1245. View

15.

Guo G, Cai Y, Zhang B, Xu R, Qiu H, Xia L . Overexpression of SGLT1 and EGFR in colorectal cancer showing a correlation with the prognosis. Med Oncol. 2010; 28 Suppl 1:S197-203. DOI: 10.1007/s12032-010-9696-8. View

16.

Wright E, Loo D, Hirayama B . Biology of human sodium glucose transporters. Physiol Rev. 2011; 91(2):733-94. DOI: 10.1152/physrev.00055.2009. View

17.

Gould G, Bell G . Facilitative glucose transporters: an expanding family. Trends Biochem Sci. 1990; 15(1):18-23. DOI: 10.1016/0968-0004(90)90125-u. View

18.

Lai B, Xiao Y, Pu H, Cao Q, Jing H, Liu X . Overexpression of SGLT1 is correlated with tumor development and poor prognosis of ovarian carcinoma. Arch Gynecol Obstet. 2011; 285(5):1455-61. DOI: 10.1007/s00404-011-2166-5. View

19.

Perez M, Praena-Fernandez J, Felipe-Abrio B, Lopez-Garcia M, Lucena-Cacace A, Garcia A . MAP17 and SGLT1 protein expression levels as prognostic markers for cervical tumor patient survival. PLoS One. 2013; 8(2):e56169. PMC: 3572015. DOI: 10.1371/journal.pone.0056169. View

20.

Scafoglio C, Hirayama B, Kepe V, Liu J, Ghezzi C, Satyamurthy N . Functional expression of sodium-glucose transporters in cancer. Proc Natl Acad Sci U S A. 2015; 112(30):E4111-9. PMC: 4522748. DOI: 10.1073/pnas.1511698112. View